Comparison of EUS-Guided Liver Biopsy With Percutaneous Liver Biopsy
Atslēgvārdi
Abstrakts
Apraksts
Currently, liver biopsy is the gold standard for determining the index of liver fibrosis in a patient with chronic liver disease, and whether the patient has progressed to cirrhosis. These biopsies are predominantly performed percutaneously. However, there are several complications related to liver biopsy, the most common of which are pain and bleeding.
There has been significant movement over the past several years to assess the utility of alternative techniques and approaches for the evaluation of liver disease. Endoscopic ultrasound (EUS) is a well-established technique for diagnostic and therapeutic evaluation of gastrointestinal and pancreaticobiliary disorders. EUS-guided liver biopsy (EUS-LB) has shown to be technically simple, safe, and provides adequate diagnostic yield for evaluation of liver disease in both children and adults. There are several advantages to EUS-LB. First, it would theoretically be less painful than the percutaneous approach, as it does not require skin puncture and also offers the comfort of sedation and analgesia. It also eliminates the need for breath hold. Furthermore, it is an image-guided approach which allows visualization and avoidance of blood vessels even 1 mm in size. Additionally, it provides an access area to a much wider segment of liver parenchyma as the entire left lobe, and the majority of the right lobe can be evaluated for possible needle puncture sites from the stomach and duodenal bulb, respectively. In addition to obtaining tissue, EUS-LB also offers the benefit of evaluating the biliary tree, gallbladder, pancreas, lymph nodes, and vascular anatomy for a more comprehensive evaluation in the same setting. Finally, in patients ultimately found to have biopsy-proven cirrhosis, it simultaneously provides the necessary variceal screening which would otherwise require an additional procedure.
The aim of this study is to prospectively perform EUS-guided liver biopsies in patients who are otherwise candidates for percutaneous biopsy. We hypothesize that (1) patients who are randomized to undergo EUS-guided liver biopsy will rate themselves as having less pain in the 48 hours following the procedure and (2) will have comparable histologic yield to a 2:1 matched cohort of patients undergoing percutaneous transjugular liver biopsies.
Datumi
| Pēdējoreiz pārbaudīts: | 09/30/2016 |
| Pirmais iesniegtais: | 10/24/2016 |
| Paredzētā reģistrācija iesniegta: | 10/25/2016 |
| Pirmais izlikts: | 10/27/2016 |
| Pēdējais atjauninājums iesniegts: | 10/25/2016 |
| Pēdējā atjaunināšana ievietota: | 10/27/2016 |
| Faktiskais studiju sākuma datums: | 12/31/2016 |
| Paredzamais primārās pabeigšanas datums: | 05/31/2018 |
| Paredzamais pētījuma pabeigšanas datums: | 11/30/2018 |
Stāvoklis vai slimība
Iejaukšanās / ārstēšana
Procedure: EUS-guided liver biopsy
Procedure: Percutaneous liver biopsy
Fāze
Roku grupas
| Roka | Iejaukšanās / ārstēšana |
|---|---|
| Active Comparator: Percutaneous liver biopsy Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo a percutaneous liver biopsy per standard protocol. | Procedure: Percutaneous liver biopsy Participants will undergo percutaneous liver biopsy per standard protocol. |
| Experimental: EUS-guided liver biopsy Participants will be referred for liver biopsy by their hepatologist/gastroenterologist. The intervention is that these participants will undergo an endoscopic ultrasound procedure per standard protocol. The liver will be identified, and Color Doppler imaging prior to needle puncture will confirm lack of significant vascular structures within the needle path. Liver biopsies using up to 1-2 passes from the left hepatic lobe using a transgastric approach and up to 1-2 passes from the right hepatic lobe using a transduodenal bulb approach will be performed. The participant will be observed in the recovery unit for up to 60 minutes after the EUS-LB, and discharged if no pain or signs of complication. | Procedure: EUS-guided liver biopsy Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time. |
Atbilstības kritēriji
| Vecums, kas piemērots studijām | 18 Years Uz 18 Years |
| Dzimumi, kas ir piemēroti studijām | All |
| Pieņem veselīgus brīvprātīgos | Jā |
| Kritēriji | Inclusion Criteria: - Age 18 years and older - Eligibility for receiving conscious sedation or monitored anesthesia care - Abnormal liver function tests with comprehensive previous evaluation (including serologic testing and cross-sectional imaging) leading to an appropriate decision to proceed with liver biopsy and/or portal pressure measurements. Exclusion Criteria: - Suspected or known malignant liver disease - Severe thrombocytopenia (platelets <50,000/microL) - Severe coagulopathy (international normalized ratio [INR] > 1.7 or other known coagulopathy) - Use of antiplatelet agents within 7 days of the procedure - Inability to provide informed consent - Pregnancy or suspected pregnancy |
Rezultāts
Primārie rezultāti
1. Change From Baseline in Pain Scores on the Universal Pain Assessment Tool (UPAT) [48 hours]
Sekundārie iznākuma mērījumi
1. Pain Medication Requirements [48 hours]
2. Histologic Yield [1 week]
